Idera Pharmaceuticals Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported income from operations of $40,000, income before income taxes of $54,000, net income of $24,000 on revenue of $6,538,000 compared to income from operations of $1,614,000, income before income taxes of $1,980,000, net income of $1,980,000 on revenue of $7,517,000 for the same period last year. For the nine months, the company reported income from operations of $3,669,000, income before income taxes of $3,785,000, net income of $3,615,000, or $0.15 per diluted share on revenue of $24,338,000 compared to income from operations of $317,000, income before income taxes of $1,145,000, net income of $1,145,000 on revenue of $20,196,000 for the same period last year.

Idera Pharmaceuticals Inc. presents preclinical data on the mechanism by which IMO 2125 was shown to induce immune activation through Toll-like Receptor 9 (TLR9). Two presentations are being made at the 60th Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, MA. Abstract 1593: 'IMO-2125, a TLR9 agonist, induces Th-1 type cytokines and interferons with potent anti-HCV activity in human peripheral blood mononuclear cells (PBMCs) and plasmacytoid dendritic cells (pDCs)' In this study, IMO-2125 induction of cytokines was evaluated in human peripheral blood mononuclear cells (hPBMCs) and plasmacytoid dendritic cells (pDCs). The data show that IMO-2125 induced high levels of endogenous interferon-alpha along with interferon-beta, interferon-lambda, and other proteins including IP-10 and 2'-5'-OAS. These IMO-2125-induced cytokines showed potent antiviral activity in the HCV replicon assay. Antiviral activity was decreased by addition of anti-interferon-alpha antibody, but only partially which suggests that other cytokines and chemokines induced by IMO-2125 also contribute to the antiviral activity.

Idera Pharmaceuticals Inc. announced the presentation of preclinical data from studies of IMO-3100 in combination with Enbrel (etanercept) in a mouse model of arthritis. IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, is a lead drug candidate that Idera is developing for potential applications in autoimmune diseases. Enbrel is an inhibitor of TNF-alpha currently used for the treatment of rheumatoid arthritis. The presentation is being made at the 2009 Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) being held in Philadelphia, PA, October 17-21.